Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in chronic coronary syndrome
NCT06421363Phase 4Not yet recruiting
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 4 trial of inclisiran in ischemic heart disease (IHD), acute coronary syndrome (ACS). Planned start Jun 2024; status: not yet recruiting.
02
Drugs
inclisiran
03
Conditions
ischemic heart disease (IHD)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06421363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421363.